<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id>
      <journal-title-group>
        <journal-title>Intensive Care Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0342-4642</issn>
      <issn pub-type="epub">1432-1238</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17668176</article-id>
      <article-id pub-id-type="pmc">3227034</article-id>
      <article-id pub-id-type="publisher-id">810</article-id>
      <article-id pub-id-type="doi">10.1007/s00134-007-0810-0</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Recombinant human activated factor VII in postpartum hemorrhagic shock: the dark side</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>van Veen</surname>
            <given-names>E. J. W.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Monteban-Kooistra</surname>
            <given-names>W. E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meertens</surname>
            <given-names>J. H. J. M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ligtenberg</surname>
            <given-names>J. J. M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tulleken</surname>
            <given-names>J. E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Zijlstra</surname>
            <given-names>J. G.</given-names>
          </name>
          <address>
            <phone>+31-50-3616161</phone>
            <fax>+31-50-3613216</fax>
            <email>j.g.zijlstra@int.umcg.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1">Intensive and Respiratory Care, University Medical Centre Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, Netherlands </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>1</day>
        <month>8</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>8</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2008</year>
      </pub-date>
      <volume>34</volume>
      <issue>1</issue>
      <fpage>211</fpage>
      <lpage>212</lpage>
      <history>
        <date date-type="accepted">
          <day>10</day>
          <month>7</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2007</copyright-statement>
      </permissions>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2008</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Sir: A&#xA0;38-year-old woman (gravida 2, para 3) was referred to our hospital because of intractable postpartum hemorrhagic shock. During this gemelli pregnancy she was admitted to the hospital three times for vaginal blood loss. Ultrasonography revealed a&#xA0;hematoma and a&#xA0;placenta close to the cervical ostium. Coagulation and platelets were normal. Because of fetal distress during spontaneous labor at 34 weeks an emergency cesarean section was performed. Vaginal hemorrhage began after abdominal closure. Management consisted of uterotonic drugs, intravenous fluids, red blood cells, and fresh frozen plasma without effect. Supravaginal hysterectomy was deemed necessary. Because of pelvic oozing the abdomen was closed after packing of the pelvis. She was still in hemorrhagic shock. Recombinant human activated factor VIIa (rFVIIa; NovoSeven) was administered twice as a&#xA0;7.2-mg intravenous bolus at an interval of 120&#x202F;min, but bleeding continued from almost all orifices. The next day she was referred. Hemodynamic instability persisted, and multiorgan failure developed. Angiography of the pelvic arteries resulted in coiling of three small arteries, but hemostasis was not achieved. On the third day tranexamic acid was added and, after lack of effect, a&#xA0;9-mg intravenous bolus of rFVIIa (90&#x202F;&#x3BC;g/kg). Coagulation parameters improved and for several hours the hemoglobin level was stable, but she developed blistering of arms, fingers, and feet with slow capillary refill. Toes, heel, and sole of the right foot became black and cold. On laparotomy packings and 9&#x202F;l blood and cloths were removed. Afterwards there was no bleeding. The ischemia worsened in a&#xA0;few days and spread to the fore foot (Fig.&#x202F;<xref rid="Fig1" ref-type="fig">1</xref>) resulting in amputation of the lower extremity. Necrosis also developed on the dorsal side of the left fore arm. Other acra were cyanotic but did not become necrotic. Since delivery she had received 48&#x202F;U red blood cells, 30&#x202F;U fresh frozen plasma and 17&#x202F;U five donors each of platelets. Multiorgan failure improved, and 19&#x202F;days after admission the patient was discharged to the ward.
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Right foot of the patient</p></caption><graphic xlink:href="134_2007_810_Fig1_HTML" id="d28e220"/></fig></p>
    <p>rFVIIa use has been reported for severe postpartum hemorrhage&#xA0;[<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Immediately after administration of the third dose of rFVIIa hemostasis was indeed reached. However, severe thromboembolic complications occurred. Although there seems to be a&#xA0;relationship in time between the onset of complications and moment of drug administration, it is hard to confirm this relationship. rFVIIa overdosing or sepsis may also play a&#xA0;role. However, there was no positive confirmation of infection.</p>
    <p>The incidence of thrombotic complications in licensed use is 1&#x2013;2%. Most thromboembolic events have followed off-label use of rFVIIa&#xA0;[<xref ref-type="bibr" rid="CR3">3</xref>]. Off-label rFVIIa is used principally in desperate situations. However, to make a&#xA0;balanced choice, even then we need to have an impression of the complication rate. Safety and efficacy in off-label use must be studied&#xA0;[<xref ref-type="bibr" rid="CR4">4</xref>]. Pregnant and postpartum women should receive special attention in these studies because of their particular coagulation condition.</p>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Franchini</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lippi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Franchi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage</article-title>
          <source>Br J Obstet Gynaecol</source>
          <year>2007</year>
          <volume>114</volume>
          <fpage>8</fpage>
          <lpage>15</lpage>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haynes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Laffan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Plaat</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Use of recombinant activated factor VII in massive obstetric haemorrhage</article-title>
          <source>Int J Obstet Anesth</source>
          <year>2007</year>
          <volume>16</volume>
          <fpage>40</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijoa.2006.07.005</pub-id>
          <pub-id pub-id-type="pmid">17126006</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Connell</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Wise</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Lozier</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Braun</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
          <article-title>Thromboembolic adverse events after use of recombinant human coagulation factor VIIa</article-title>
          <source>JAMA</source>
          <year>2006</year>
          <volume>295</volume>
          <fpage>293</fpage>
          <lpage>298</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.295.3.293</pub-id>
          <pub-id pub-id-type="pmid">16418464</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Buller</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review</article-title>
          <source>Crit Care Med</source>
          <year>2005</year>
          <volume>33</volume>
          <fpage>883</fpage>
          <lpage>890</lpage>
          <pub-id pub-id-type="doi">10.1097/01.CCM.0000159087.85970.38</pub-id>
          <pub-id pub-id-type="pmid">15818119</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
